BioNTech said that its VEGF bispecific sets it apart from competitors because of its mechanism and how it plans to ...

Arcus Biosciences (RCUS) announced results from Part 1 of ARC-10, a randomized, open-label, three-arm study evaluating domvanalimab, an ...

A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses.

(RTTNews) - Arcus Biosciences, Inc. (RCUS), Tuesday announced results from part 1 of ARC-10, evaluating the effects of the combination of Domvanalimab and Zimberelimab versus Zimberelimab or ...

A team from The Institute of Cancer Research, London, has developed a new immuno-PET imaging technique that could spot which ...

The following is a summary of "Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and ...

Despite the PDUFA date being extended by three months for Merus’ zenocutuzumab, Truist Securities analyst Asthika ...

INBX's two main pipeline candidates are entering critical late-stage trials with data readouts expected in mid- to late-2025. Click here to read my analysis.

TACTI-003 Cohort B: Eftilagimod Alpha (Soluble LAG-3) and Pembrolizumab in First-Line Recurrent or Metastatic Head & Neck ...

Media Release SYDNEY, AUSTRALIA, Oct. 28, 2024 (GLOBE NEWSWIRE) -- (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a ...

Israeli researchers believe they've found a way of identifying and removing senescent cells by adapting a new generation of ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.